Athernal Bio
PrivateLast Round
VC Round
Oct 1, 2025
Total Funding Raised
$12,600
Company Overview
Athernal Bio operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a VC Round in October 2025.
Athernal Bio is a biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a blood cancer precursor condition, with the goal of preventing cancer before it starts.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Athernal Bio Comparables
Compare Athernal Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novartis | 63% | |
| Bristol Myers Squibb | 61% | |
| Servier | 48% |
For institutional investors. Book with your work email.
Athernal Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 1, 2025 | ||||
| Accelerator | May 30, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Athernal Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Accelerate@Babraham | Accelerator |
| Delin Ventures | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
$4.7M round led by Delin Ventures
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
Athernal Bio is developing targeted immunotherapies that harness the immune system to eliminate high-risk cells before they become malignant, with Innovate UK funding supporting preclinical validation of its lead candidate and advancement toward the clinic in collaboration with UK academic and research groups in the United Kingdom on Sep 9th '26.
- receives_financingSep 9, 2026
On Sep 9th '26, Athernal Bio receives a $948K non-dilutive Innovate UK Growth Catalyst grant in the United Kingdom to advance preclinical studies for its lead immunotherapy programme, alongside continued support from Delin Ventures.
For institutional investors. Book with your work email.
Athernal Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Athernal Bio's valuation, stock price, and market status.
Is Athernal Bio a public or private company?
Athernal Bio is a private company.
What is the current stock price of Athernal Bio?
Athernal Bio is a private company, so its shares have no public market price. Caplight tracks Athernal Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Athernal Bio worth (valuation)?
Valuation information for Athernal Bio is not publicly available.
Can I buy Athernal Bio stock?
Athernal Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Athernal Bio's last funding round?
Athernal Bio's most recent funding round was VC Round on October 1, 2025.
Who are the main investors in Athernal Bio?
Key investors in Athernal Bio include Delin Ventures.
Will Athernal Bio IPO soon?
No public IPO plans have been announced for Athernal Bio.
How can I track Athernal Bio secondary market activity?
Caplight tracks bids, offers, and trades in Athernal Bio's shares on secondary markets.